Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Transitional Cell CarcinomaEndometrial Undifferentiated CarcinomaRecurrent Uterine Corpus Carcinoma
Interventions
BIOLOGICAL

Dalantercept

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (30)

10065

Memorial Sloan-Kettering Cancer Center, New York

19718

Christiana Care Health System-Christiana Hospital, Newark

19958

Beebe Medical Center, Lewes

21921

Union Hospital of Cecil County, Elkton

27157

Wake Forest University Health Sciences, Winston-Salem

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

28204

Novant Health Presbyterian Medical Center, Charlotte

32803

Florida Hospital Orlando, Orlando

34239

Sarasota Memorial Hospital, Sarasota

44060

Lake University Ireland Cancer Center, Mentor

44106

Case Western Reserve University, Cleveland

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

46260

Saint Vincent Hospital and Health Care Center, Indianapolis

57104

Sanford Cancer Center-Oncology Clinic, Sioux Falls

Sanford NCI Community Oncology Research Program of the North Central Plains, Sioux Falls

60637

University of Chicago Comprehensive Cancer Center, Chicago

62526

Decatur Memorial Hospital, Decatur

63110

Washington University School of Medicine, St Louis

68114

Nebraska Methodist Hospital, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

94115

UCSF Medical Center-Mount Zion, San Francisco

98104

Pacific Gynecology Specialists, Seattle

98109

Seattle Cancer Care Alliance, Seattle

98133

Northwest Hospital, Seattle

98195

University of Washington Medical Center, Seattle

04102

Maine Medical Center-Bramhall Campus, Portland

02905

Women and Infants Hospital, Providence

57117-5134

Sanford USD Medical Center - Sioux Falls, Sioux Falls

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT01642082 - Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter